Bristol-Myers Squibb (NY:BMY)

58.90 -2.25 (-3.69%)

Delayed Quote Updated: 1:15 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

93 94 Next >

3 Large-Cap Stocks Skating on Thin Ice

July 02, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering ↗

June 28, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.

Via Chartmill

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers ↗

June 27, 2025

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.

Via Benzinga

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

June 26, 2025

From Bristol Myers Squibb

Via Business Wire

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug ↗

June 25, 2025

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

Via Benzinga

Topics Fraud Lawsuit

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering ↗

June 23, 2025

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.

Via Chartmill

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

June 18, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks

June 18, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

June 17, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers ↗

June 16, 2025

The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial.

Via Stocktwits

Top S&P500 movers in Monday's session ↗

June 16, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

June 16, 2025

From Bristol Myers Squibb

Via Business Wire

2 Beaten-Down Dividend Stocks to Buy Right Now ↗

June 16, 2025

Via The Motley Fool

Topics Economy World Trade

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal ↗

June 12, 2025

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Via Benzinga

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

June 12, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

June 12, 2025

From Bristol Myers Squibb

Via Business Wire

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

June 11, 2025

From Bristol Myers Squibb

Via Business Wire

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus

June 10, 2025

From Philogen S.p.A.

Via GlobeNewswire

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2025

Via The Motley Fool

Topics Intellectual Property

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering ↗

June 06, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.

Via Chartmill

Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis ↗

June 05, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

June 05, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗

June 04, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Via Benzinga

Why BioNTech Stock Soared Today ↗

June 02, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.

Via The Motley Fool

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug ↗

June 02, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.

Via Benzinga

Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug ↗

June 02, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.

Via Stocktwits

Topics Government

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

June 02, 2025

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.